Currently, Kronos Bio Inc [KRON] is trading at $0.87, down -0.23%. An important factor to consider is whether the stock is rising or falling in short-term value. The KRON shares have gain 30.14% over the last week, with a monthly amount glided 19.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kronos Bio Inc [NASDAQ: KRON] stock has seen the most recent analyst activity on November 14, 2024, when TD Cowen downgraded its rating to a Hold. Previously, Piper Sandler downgraded its rating to Neutral on November 14, 2024, and dropped its price target to $1. On September 14, 2022, Berenberg initiated with a Buy rating and assigned a price target of $12 on the stock. H.C. Wainwright initiated its recommendation with a Buy and recommended $35 as its price target on June 24, 2021. Piper Sandler started tracking with a Overweight rating for this stock on November 03, 2020, and assigned it a price target of $50. In a note dated November 03, 2020, Jefferies initiated an Buy rating and provided a target price of $36 on this stock.
This stock has fluctuated between a low of $0.65 and a high of $1.60 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $1.63 within the next 12 months. Kronos Bio Inc [NASDAQ: KRON] shares were valued at $0.87 at the most recent close of the market. An investor can expect a potential return of 87.36% based on the average KRON price forecast.
Analyzing the KRON fundamentals
Trailing Twelve Months sales for Kronos Bio Inc [NASDAQ:KRON] were 9.19M which represents -26.03% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -7.65%, Pretax Profit Margin comes in at -7.02%, and Net Profit Margin reading is -7.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.64 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8551 points at the first support level, and at 0.8402 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8868, and for the 2nd resistance point, it is at 0.9036.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kronos Bio Inc [NASDAQ:KRON] is 12.93. On the other hand, the Quick Ratio is 12.93, and the Cash Ratio is 11.62. Considering the valuation of this stock, the price to sales ratio is 5.77, the price to book ratio is 0.66.
Transactions by insiders
Recent insider trading involved KNOBELMAN DEBORAH, President & Interim CEO, that happened on Jun 05 ’25 when 24838.0 shares were sold. PRESIDENT & CEO, BISCHOFBERGER NORBERT W completed a deal on Jun 27 ’24 to buy 0.41 million shares. Meanwhile, PRESIDENT & CEO BISCHOFBERGER NORBERT W bought 0.2 million shares on Jun 28 ’24.
